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Table 1
Standard pediatric vaccines compatible
with PCV13.4–8
Diphtheria
Tetanus
Acellular or whole cell pertussis
Haemophilus inﬂuenzae type b
Inactivated poliomyelitis
Hepatitis B
Meningococcal serogroup C
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CV13: proven efﬁcacy and safety
This discussion is based on a presentation given at a satellite
ymposium held in Buenos Aires, Argentina, on November 20,
009, at the 6th World Congress of the World Society for Pediatric
nfectious Diseases.
Second-generation pneumococcal conjugate vaccines (PCVs),
ncluding 10-valent PCV and 13-valent PCV (PCV13), have recently
een licensed in multiple countries worldwide. PCV13 is an
ligosaccharide/polysaccharide capsular antigen conjugated with
he nontoxic mutant protein CRM197 of diphtheria toxoid, the
ame carrier protein used in the 7-valent vaccine (PCV7).
In addition to the 7 Streptococcus pneumoniae serotypes covered
n PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13 also includes
erotypes 1, 3, 5, 6A, 7F, and 19A. The inclusion of serotypes
A and 19A in PCV13 will provide additional direct pediatric
overage, and serotypes 1, 3, 5, and 7F will provide additional
titis media coverage. Coverage of all of these serotypes will
ollectively provide generally improved global coverage against
nvasive pneumococcal disease (IPD).
Studies conducted in Italy1 and Spain2 have demonstrated
hat the immunogenicity of PCV13 in a 2+1 schedule is compa-
able to that of PCV7. PCV7 administered in a 2+1 schedule has
ocumented efﬁcacy against IPD.3 Because PCV13 is designed to
e interchangeable with PCV7 at any point in the immunization
chedule, countries that are using PCV7 in the 2+1 schedule should
e able to transition directly to PCV13. Furthermore, PCV13 was
ound to be noninferior to PCV7 when given concomitantly with
ost of the standard pediatric vaccines (Table 1), and it did not
dversely affect the safety and/or immune responses of any of the
oadministered vaccines.4–8Varicella
PCV13=13-valent pneumococcal con-
jugate vaccine.
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Preventing pneumococcal disease in adults
This discussion is based on a presentation given at a satellite
symposium held in Buenos Aires, Argentina, on November 20,
2009, at the 6th World Congress of the World Society for Pediatric
Infectious Diseases.
Pneumococcal infection accounts for about 500,000 cases of
pneumonia each year in the United States and is associated with
considerable morbidity and mortality.1 Pneumonia symptoms
(i.e., fever, myalgia, dyspnea, cough, and fatigue) tend to persist,
with median times to resolution ranging from 3 days for fever to
14 days for cough and fatigue; 35% of patients have ≥1 unresolved
symptom at day 28.2 The 30-day mortality rate among patients
with pneumococcal pneumonia admitted to the intensive care
unit remains high compared with that of patients admitted to the
general ward (23% vs 4%, respectively; P<0.001).3The 23-valent pneumococcal polysaccharide vaccines (PPSVs)
currently available were licensed in 1983, replacing the earlier
14-valent formulation that was licensed in 1977.1 The Centers for
Disease Control and Prevention Advisory Committee on Immu-
Highlights of the 6th World Congress of the WSPID / Internat
Table 1
High-risk indications for 23-valent PPSV immunization: persons 2 through 64 years
of age.1
• Chronic cardiovascular disease (e.g., congestive heart failure,
cardiomyopathy)
• Chronic pulmonary disease (e.g., chronic obstructive pulmonary
disease, emphysema)
• Chronic liver disease (e.g., cirrhosis, disease resulting from alcohol
abuse)
• Diabetes mellitus
• Asthma with chronic bronchitis, emphysema, long-term use of
corticosteroids
• Functional or anatomic asplenia (e.g., sickle cell disease, splenectomy)
• Chronic cerebrospinal ﬂuid leaks (from congenital lesions, skull
fractures, neurosurgical procedures)
• Immunocompromising conditions (e.g., congenital immunodeﬁciency,
AIDS, symptomatic or asymptomatic HIV infection, leukemia,
lymphoma, Hodgkin’s disease, multiple myeloma, generalized
malignancy, chronic renal failure, nephrotic syndrome, organ or bone
marrow transplantation)
• Use of certain therapies (e.g., immunosuppressive chemotherapy,
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Ralkylating agents, antimetabolites, systemic corticosteroids)
• Residents of nursing homes or long-term care facilities
PSV=pneumococcal polysaccharide vaccine.
ization Practices1 recommends a single dose of the 23-valent
PSV for adults ≥65 years of age who have not previously been
accinated or whose vaccination status is unknown, and for
ersons 2 through 64 years of age with certain high-risk conditions
Table 1). Routine revaccination is not recommended; however,
single revaccination with 23-valent PPSV is recommended for
dults ≥65 years of age who have not received the vaccine within
years and who were ﬁrst vaccinated before age 65. Revaccination
s also recommended for persons 2 through 64 years of agewho are
t the highest risk for serious pneumococcal disease (see Table 1),
rovided that 5 years have elapsed since the initial vaccinationwas
eceived.1
A recent study4 evaluated the safety and tolerability of 13-
alent pneumococcal conjugate vaccine (PCV13) administered
oncomitantly with the trivalent inactivated inﬂuenza vaccine
TIV) and the immunogenicity of the combination versus either
iven alone. Results of the study showed that the immune
esponse of PCV13+TIV was comparable to PCV13 or TIV given
lone. Subjects aged ≥65 years (n =1160) were randomized to
eceive PCV13+TIV followed by placebo or TIV+placebo followed
y PCV13 at 0 and 1 month. Inﬂuenza vaccine titres and PCV13
erotype titres were measured before and 1 month after vacci-
ation. The immune response to TIV was comparable whether
t was given alone or with PCV13, based on the percentage of
ubjects with a 4-fold increase in titres for concomitant vaccine
ntigens after receiving PCV13+TIV compared with TIV+placebo
nd the percentage of subjects achieving a hemagglutination
nhibition titre ≥40 after receiving PCV13+TIV. A comparison of
neumococcal immunoglobulin G geometric mean concentrations
month after PCV13+TIV and PCV13 given alone showed that the
mmune response was comparable. Local reactions were mainly
ild and were comparable between PCV13+TIV and PCV13 alone
46.9% and46.6%, respectively). However, the incidence of systemic
eactions was higher in subjects receiving both vaccines compared
ith either vaccine alone (PCV13+TIV 60.2% vs TIV 50.7% and
CV13 48.6%).
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Expanding the options in pneumococcal immunization
A 10-valent pneumococcal polysaccharide conjugate vaccine
(PCV10) was recently licensed in Europe based on immunogenicity
comparable to the 7-valent pneumococcal conjugate vaccine
(PCV7). PCV10 contains serotypes 1, 5, and 7F, in addition to those
contained in PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F). Clinical studies
evaluating the immunogenicity of PCV10 compared with that of
PCV7 indicate that antibody levels for the common serotypes were
similar.1 Immunogenicity responses to serotypes 5 and 7F were
high, whereas responses to serotype 1 were somewhat lower.
PCV10 also induced high antibody responses against protein D. Fol-
lowing thebooster dose, almost all subjects reachedpredetermined
enzyme-linked immunosorbent assay (ELISA) and opsonophago-
cytic assay (OPA) antibody thresholds. When coadministered with
common pediatric vaccines, PCV10 was comparable to PCV7 in
terms of compatibility, with no difference in antibody responses
being observed with either pneumococcal vaccine.
PCV10 is designed to provide protection against mucosal
disease caused by Streptococcus pneumoniae, such as acute otitis
media (AOM) and pneumonia, as well as those caused by non-
typeable Haemophilus inﬂuenzae (NTHi), such as AOM. These 2
organisms account for ≥80% of bacterial AOM cases worldwide.2
In the Pneumococcal Otitis Efﬁcacy Trial (POET),2 an 11-valent
prototype vaccine was found to provide protection against AOM
caused by both S pneumoniae and NTHi, reducing conﬁrmed AOM
episodes by one third and signiﬁcantly reducing episodes caused
by NTHi by 35% (P=0.041).
A controlled safety study3 of this 11-valent vaccine was con-
ducted in 12,194 Filipino infants who received 3 doses of the
vaccine or placebo at 6, 10, and 14 weeks of age. The majority of
serious adverse events (AEs) or clinical episodes (pneumonia, gas-
troenteritis, suspected sepsis, meningitis, or other severe illness
necessitating hospital admission) occurredwithin 28 days of vacci-
nation. Therewas anexcess of seriousAEs following receipt of 1 or 2
doses of the vaccine, but not after the third dose. Acute lower respi-
ratory infections were diagnosed most often during follow-up hos-
pital investigations. The 11-valent vaccine did not appear to have
a protective effect against viral-associated lower respiratory tract
infection; interestingly, there was an excess of cytomegalovirus.4
Prymula et al5 conducted a study on the nasopharyngeal
carriage of S pneumoniae vaccine serotypes following vaccination
with PCV10. Subjects were infants primed at age 3, 4, and 5
months with PCV10 followed by a booster at 12–15 months of
age or age-matched controls who received a ﬁrst dose of the
meningococcal ACWY-TT vaccine at 12–15 months of age. Carriage
of S pneumoniae vaccine serotypes were assessed before the
meningococcal vaccination or the PCV10 booster vaccination and
at 1, 3, 7, and 12months after vaccination. Carriage of S pneumoniae
vaccine serotypes in the second year of life was reduced by 22–35%
in subjects who received PCV10, although carriage of nonvaccine
serotypes tended to increase in this group, similar to previous
experiences with the 7-valent pneumococcal conjugate vaccine.PCV10 also has been shown to be immunogenic and well
tolerated when used in the primary immunization of both pre- and
full-term infants. In an open study6 designed to evaluate immune
responses and safety of the PCV10 booster vaccination, children
